Cell Biotech Co. Ltd (049960) — Cash Flow-to-Debt Ratio
Cell Biotech Co. Ltd (049960) has a Cash Flow-to-Debt Ratio of 0.56x as of September 2025, meaning its operating cash flow of ₩4.15 Billion could theoretically repay 1% of its total liabilities (₩7.46 Billion) in one year. Explore 049960 long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cell Biotech Co. Ltd Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Cell Biotech Co. Ltd across 14 annual periods. Also explore Cell Biotech Co. Ltd assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Cell Biotech Co. Ltd (2011–2024)
Year-by-year debt coverage analysis for Cell Biotech Co. Ltd. For market capitalisation and broader financial context, see Cell Biotech Co. Ltd market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 3.09x | ₩19.27 Billion | ₩6.23 Billion | ▲ +127.8% |
| 2023 | 1.36x | ₩7.82 Billion | ₩5.76 Billion | ▼ -17.9% |
| 2022 | 1.65x | ₩12.81 Billion | ₩7.75 Billion | ▼ -31.3% |
| 2021 | 2.41x | ₩14.89 Billion | ₩6.19 Billion | ▲ +33.8% |
| 2020 | 1.80x | ₩9.56 Billion | ₩5.32 Billion | ▼ -17.3% |
| 2019 | 2.18x | ₩10.23 Billion | ₩4.70 Billion | ▲ +0.0% |
| 2018 | 2.18x | ₩13.98 Billion | ₩6.42 Billion | ▼ -39.3% |
| 2017 | 3.59x | ₩22.53 Billion | ₩6.28 Billion | ▲ +27.1% |
| 2016 | 2.82x | ₩17.99 Billion | ₩6.38 Billion | ▼ -3.9% |
| 2015 | 2.94x | ₩18.24 Billion | ₩6.21 Billion | ▲ +55.4% |
| 2014 | 1.89x | ₩9.91 Billion | ₩5.24 Billion | ▼ -23.3% |
| 2013 | 2.46x | ₩8.99 Billion | ₩3.65 Billion | ▲ +55.1% |
| 2012 | 1.59x | ₩6.17 Billion | ₩3.88 Billion | ▲ +45.1% |
| 2011 | 1.10x | ₩5.45 Billion | ₩4.98 Billion | — |